These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 29307225)

  • 1. Passive and active antibody studies in primates to inform HIV vaccines.
    Hessell AJ; Malherbe DC; Haigwood NL
    Expert Rev Vaccines; 2018 Feb; 17(2):127-144. PubMed ID: 29307225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein.
    van Haaren MM; McCoy LE; Torres JL; Lee W; Cottrell CA; Copps JL; van der Woude P; Yasmeen A; de Taeye SW; Torrents de la Peña A; Moore JP; Burton DR; Klasse PJ; Ward AB; Sanders RW; van Gils MJ
    J Virol; 2021 Aug; 95(17):e0009421. PubMed ID: 34076487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques.
    Dennis M; Eudailey J; Pollara J; McMillan AS; Cronin KD; Saha PT; Curtis AD; Hudgens MG; Fouda GG; Ferrari G; Alam M; Van Rompay KKA; De Paris K; Permar S; Shen X
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical question for HIV vaccine development: which antibodies to induce?
    Zolla-Pazner S
    Science; 2014 Jul; 345(6193):167-8. PubMed ID: 25013066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress toward active or passive HIV-1 vaccination.
    Escolano A; Dosenovic P; Nussenzweig MC
    J Exp Med; 2017 Jan; 214(1):3-16. PubMed ID: 28003309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.
    Burton S; Spicer LM; Charles TP; Gangadhara S; Reddy PBJ; Styles TM; Velu V; Kasturi SP; Legere T; Hunter E; Pulendran B; Amara R; Hraber P; Derdeyn CA
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Antibody Response against HIV-1.
    Overbaugh J; Morris L
    Cold Spring Harb Perspect Med; 2012 Jan; 2(1):a007039. PubMed ID: 22315717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.
    Stephenson KE; Wagh K; Korber B; Barouch DH
    Annu Rev Immunol; 2020 Apr; 38():673-703. PubMed ID: 32340576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
    Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
    J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress in immune-based interventions to prevent HIV-1 transmission to children.
    Voronin Y; Jani I; Graham BS; Cunningham CK; Mofenson LM; Musoke PM; Permar SR; Scarlatti G
    J Int AIDS Soc; 2017 Dec; 20(4):. PubMed ID: 29282882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.
    Rudicell RS; Kwon YD; Ko SY; Pegu A; Louder MK; Georgiev IS; Wu X; Zhu J; Boyington JC; Chen X; Shi W; Yang ZY; Doria-Rose NA; McKee K; O'Dell S; Schmidt SD; Chuang GY; Druz A; Soto C; Yang Y; Zhang B; Zhou T; Todd JP; Lloyd KE; Eudailey J; Roberts KE; Donald BR; Bailer RT; Ledgerwood J; ; Mullikin JC; Shapiro L; Koup RA; Graham BS; Nason MC; Connors M; Haynes BF; Rao SS; Roederer M; Kwong PD; Mascola JR; Nabel GJ
    J Virol; 2014 Nov; 88(21):12669-82. PubMed ID: 25142607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies against HIV -- back in the major leagues?
    Ferrantelli F; Ruprecht RM
    Curr Opin Immunol; 2002 Aug; 14(4):495-502. PubMed ID: 12088685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis.
    Dai K; He L; Khan SN; O'Dell S; McKee K; Tran K; Li Y; Sundling C; Morris CD; Mascola JR; Karlsson Hedestam GB; Wyatt RT; Zhu J
    mBio; 2015 Nov; 6(6):e01375-15. PubMed ID: 26530382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.
    Rademeyer C; Korber B; Seaman MS; Giorgi EE; Thebus R; Robles A; Sheward DJ; Wagh K; Garrity J; Carey BR; Gao H; Greene KM; Tang H; Bandawe GP; Marais JC; Diphoko TE; Hraber P; Tumba N; Moore PL; Gray GE; Kublin J; McElrath MJ; Vermeulen M; Middelkoop K; Bekker LG; Hoelscher M; Maboko L; Makhema J; Robb ML; Abdool Karim S; Abdool Karim Q; Kim JH; Hahn BH; Gao F; Swanstrom R; Morris L; Montefiori DC; Williamson C
    PLoS Pathog; 2016 Jul; 12(7):e1005742. PubMed ID: 27434311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systems serology for evaluation of HIV vaccine trials.
    Ackerman ME; Barouch DH; Alter G
    Immunol Rev; 2017 Jan; 275(1):262-270. PubMed ID: 28133810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibodies and control of HIV: moves and countermoves.
    Hessell AJ; Haigwood NL
    Curr HIV/AIDS Rep; 2012 Mar; 9(1):64-72. PubMed ID: 22203469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.
    Malherbe DC; Pissani F; Sather DN; Guo B; Pandey S; Sutton WF; Stuart AB; Robins H; Park B; Krebs SJ; Schuman JT; Kalams S; Hessell AJ; Haigwood NL
    J Virol; 2014 Nov; 88(22):12949-67. PubMed ID: 25210191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.